Aug 2026
Empagliflozin Reduces Post-Myocardial Infarction Inflammation via BDH1/β-Hydroxybutyrate-Mediated NF-κB Modulation in Macrophages and the Heart.
Empagliflozin (EMPA), a sodium-glucose cotransporter 2 (SGLT2) inhibitor, demonstrates cardioprotective effects in heart failure, and recent trials suggest benefits in acute myocardial infarction (MI). However, the mechanisms underlying its efficacy, particularly its impact on the post-MI inflammatory response, are not...
Ji'e Yang, Ke Meng, Guohong Wu et al.
· Journal of Cardiovascular Ph... · 0 citations